John B Liao

9PUBLICATIONS
48CO-AUTHORS
Molecular targetsPredictive and prognostic markersInnate immunityCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|May 15, 2026
Trastuzumab deruxtecan in HER2-expressing gynecologic cancers from DESTINY-PanTumor02: antitumor activity, safety, and exploratory biomarker analyses.

|May 04, 2026
Safety and immunogenicity of a tri-antigen vaccine targeting IGFBP-2, HER2, and IGF-IR in participants with non-metastatic breast cancer.

|Nov 09, 2024
Magnitude of antigen-specific T-cell immunity the month after completing vaccination series predicts the development of long-term persistence of antitumor immune response.

John B Liao, James Y Dai, Jessica L Reichow

|Jun 09, 2023
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gynecologic cancer.

Mary L Disis, Sarah F Adams, Jyoti Bajpai

|Mar 06, 2023
Timing and duration of bevacizumab treatment and survival in patients with recurrent ovarian, fallopian tube, and peritoneal cancer: a multi-institution study.

Talayeh S Ghezelayagh, Emily S Wu, Emma L Barber

|Sep 17, 2021
Pembrolizumab with low-dose carboplatin for recurrent platinum-resistant ovarian, fallopian tube, and primary peritoneal cancer: survival and immune correlates.

John B Liao, William R Gwin, Renata R Urban

Pageof 2

Frequent Collaborators

3 joint publications

Sasha E Stanton

2 joint publications

Renata R Urban

2 joint publications

Pam Paley

2 joint publications

Emese Zsiros